CINRYZE Rx

Select the drug indication to add to your list

CINRYZE

Hereditary angioedema
Only 4 drugs may be compared at once

Generic Name and Formulations:

C1 esterase inhibitor (human) 500 Units/vial; lyophilized pwd for IV infusion after reconstitution; preservative-free.

Company:

Shire US, Inc.

Select therapeutic use:

Indications for CINRYZE:

Routine prophylaxis against angioedema attacks in patients ≥6yrs with hereditary angioedema (HAE).

Adult:

Give by IV infusion at a rate of 1mL/min (10mins). ≥12yrs: 1000 Units every 3–4 days. May consider doses up to 2500 Units (max 100 Units/kg) every 3–4 days if inadequate response.

Children:

<6yrs: not established. Give by IV infusion at a rate of 1mL/min (5mins). 6–11yrs: 500 Units every 3–4 days. May adjust dose up to 1000 Units every 3–4 days based on response.

Warnings/Precautions:

Contains human plasma; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease agent). Have epinephrine available to treat hypersensitivity reactions. Monitor patients with known risk factors for thrombotic events. Pregnancy. Nursing mothers.

Pharmacological Class:

C1 inhibitor.

Adverse Reactions:

Headache, nausea, rash, vomiting, fever; thrombotic events, hypersensitivity reactions (may be severe; discontinue if occur).

Note:

To report infections that may have been transmitted by Cinryze, call CinryzeSolutions at (877) 945-1000.

Generic Availability:

NO

How Supplied:

Single-use vial—1

CINRYZE 500 units vials (Qty:30)

appx. price $93838.00